Alector, Inc. (ALEC)

Market Cap	355.99M
Revenue (ttm)	61.51M
Net Income (ttm)	-158.41M
Shares Out	97.93M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	503,156
Open	3.840
Previous Close	3.850
Day's Range	3.602 - 3.840
52-Week Range	3.602 - 8.900
Beta	0.66
Analysts	Strong Buy
Price Target	17.75 (+388.31%)
Earnings Date	Nov 6, 2024

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2019
• Employees: 244
• Stock Exchange: NASDAQ
• Ticker Symbol: ALEC
• Website: https://www.alector.com

Financial Performance

In 2023, Alector's revenue was $97.06 million, a decrease of -27.36% compared to the previous year's $133.62 million. Losses were -$130.39 million, -2.19% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ALEC stock is "Strong Buy." The 12-month stock price forecast is $17.75, which is an increase of 388.31% from the latest price.

Price Target

$17.75

(388.31% upside)

Analyst Consensus: Strong Buy